Intec Pharma Ltd (NASDAQ:NTEC) rose 2.4% on Monday . The company traded as high as $6.18 and last traded at $6.06, with a volume of 78,227 shares traded. The stock had previously closed at $5.92.

Separately, Zacks Investment Research downgraded Intec Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th.

The stock’s market capitalization is $71.44 million. The firm has a 50 day moving average price of $5.15 and a 200-day moving average price of $4.30.

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.